Physician profile
Jane Lee
NPI 1245741552
$3,624.07
in general payments reported to CMS, 2019-2025
16 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $253 · 2023: $409 · 2024: $1,370 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,353.52 | 2021-2025 | |
| Lilly USA, LLC | $366.50 | 2023-2025 | Omvoh |
| Zimmer Biomet Holdings, INC. | $263.75 | 2021 | |
| Pfizer INC. | $261.57 | 2024-2025 | |
| Genzyme Corporation | $223.09 | 2022-2025 | |
| Gilead Sciences, INC. | $201.52 | 2022-2025 | |
| Madrigal Pharmaceuticals | $192.36 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $178.68 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.47 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $138.94 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $81.61 | 2023-2024 | Talicia |
| Ipsen Biopharmaceuticals, INC | $65.09 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $64.64 | 2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $41.12 | 2024-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $32.06 | 2025 | Uzedy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $18.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.